Instead, these studies both suggest that suppressing the level of IL-8 signalling capacity within the microenvironment of the tumour clearly enhances the therapeutic benefit of taxanes, mediated through a pronounced suppression of angiogenesis within the tumour. The gene discussed is CXCL8; the disease is neoplasm.